ArticleInfection and drug resistance2022
Ceftazidime-Avibactam versus Colistin for the Treatment of Infections Due to Carbapenem-Resistant Enterobacterales: A Multicenter Cohort Study.
Article in Infection and drug resistance, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Effectiveness and safety of meropenem-vaborbactam versus ceftazidime-avibactam in multidrug-resistant Gram-negative infections: a systematic review and meta-analysis with trial sequential analysis.Antimicrobial agents and chemotherapy · 2026Pooled it
- Pooled it
- Risk of Lichen Sclerosus and Lichen Planus in Patients Receiving Immune Checkpoint Inhibitors.International journal of environmental research and public health · 2022Pooled it
- Mortality and cost of therapy of carbapenem susceptible vs resistant Gram-negative infections among hospitalised patients in India: a multicentric surveillance (2022-2025).The Lancet regional health. Southeast Asia · 2026Article
- Efficacy and safety of ceftazidime-avibactam in carbapenem-resistant gram-negative bacilli sepsis according to infection site.American journal of translational research · 2026Article
- Real-world study of adverse events associated with ceftazidime/avibactam based on the U.S. Food and Drug Administration adverse event reporting system database.Frontiers in cellular and infection microbiology · 2026Article
- Hidden Toll of CRE Colonization: Tripled Three-Year Mortality Risk and Increased Bloodstream Infection Burden After Allo-HSCT-A Propensity-Adjusted Study.Infection and drug resistance · 2026Article
- Article
- Efficacy and safety of ceftazidime-avibactam versus standard antibiotic therapy for resistant Gram-negative bacterial infections: a systematic review and meta-analysis.Journal of thoracic disease · 2025Article
- Ceftazidime-Avibactam Versus Colistin for the Treatment of Multidrug-ResistantPharmaceuticals (Basel, Switzerland) · 2025Article
- Treatment with Ceftazidime-Avibactam for Lower Respiratory Tract Infections Caused by the Multidrug-Resistant Gram-Negative Bacteria in the Intensive Care Unit.Infection and drug resistance · 2025Article
- Investigating Gram-negative bacilli isolates' sensitivity to ceftazidime/avibactam.Journal of family medicine and primary care · 2025Article
- Efficacy of ceftazidime/avibactam versus other antimicrobial agents for treating multidrug- resistantFrontiers in cellular and infection microbiology · 2025Observational
- Ceftazidime-avibactam: Combination therapy versus monotherapy in the challenge of pneumonia caused by carbapenem-resistantHeliyon · 2024Article
- Article
- Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Klebsiella Pneumoniae Infection: A Retrospective, Single Center Study.Infection and drug resistance · 2024Article
- Ceftazidime-avibactam induced renal disorders: past and present.Frontiers in pharmacology · 2024Review
- Treatment of a challenging NDM and OXA-48-producingIDCases · 2024Article
- Cost-effectiveness analysis of ceftazidime avibactam versus colistin in carbapenem-resistant enterobacteriaceae in Iran.Cost effectiveness and resource allocation : C/E · 2023Article
- Antibiotic Susceptibility Surveillance in the Punjab Province of Pakistan: Findings and Implications.Medicina (Kaunas, Lithuania) · 2023Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe aim of this study was to compare the safety and effectiveness of ceftazidime-avibactam (CAZ-AVI) to colistin-based regimen in the treatment of infections caused by carbapenem-resistant Enterobacterales (CRE).
methodsThis was a retrospective, multicenter, observational cohort study of inpatients who received either CAZ-AVI or intravenous colistin for treatment of infections due to CRE. The study was conducted in 5 tertiary care hospitals in Saudi Arabia. Main study outcomes included in-hospital mortality, clinical cure at end of treatment, and acute kidney injury (AKI). Univariate analysis and multivariate logistic regression model were conducted to assess the independent impact of CAZ-AVI on the clinical outcome.
resultsA total of 230 patients were included in this study: 149 patients received CAZ-AVI and 81 patients received colistin-based regimen. Clinical cure (71% vs 52%; P = 0.004; OR, 2.29; 95% CI, 1.31-4.01) was significantly more common in patients who received CAZ-AVI. After adjusting the difference between the two groups, treatment with CAZ-AVI is independently associated with clinical cure (adjusted OR, 2.75; 95% CI, 1.28-5.91). In-hospital mortality (35% vs 44%; P = 0.156; OR, 0.67; 95% CI, 0.39-1.16) was lower in patients who received CAZ-AVI but the difference was not significant. AKI (15% vs 33%; P = 0.002; OR, 0.37; 95% CI, 0.19-0.69) was significantly less common in patients who received CAZ-AVI.
conclusionCAZ-AVI is associated with higher rate of clinical cure and lower rate of AKI compared to colistin. Our findings support the preferential use of CAZ-AVI over colistin-based regimen for treating these infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.